Seck Insa, Nguemo Filomain
Department of Chemistry, Faculty of Sciences and Technics, Cheikh Anta Diop University of Dakar, Dakar, Senegal.
Institute for Neurophysiology, University of Cologne, Cologne, Germany.
Results Chem. 2021 Jan;3:100132. doi: 10.1016/j.rechem.2021.100132. Epub 2021 Apr 22.
The expansion of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), COVID-19 (coronavirus disease 2019), or 2019-nCoV (2019 novel coronavirus) is a global concern over its pandemic potential. The need for therapeutic alternatives to stop this new pandemic is urgent. Nowadays, no efficacious therapy is available, and vaccines and drugs are underdeveloped to cure or prevent SARS-CoV-2 infections in many countries. Some vaccines candidates have been approved; however, a number of people are still skeptical of this coronavirus vaccines. Probably because of issues related to the quantity of the vaccine and a possible long-term side effects which are still being studied. The previous pandemics of infections caused by coronavirus, such as SARS-CoV in 2003, the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, HCoV-229E, and HCoV-OC43 were described in the 1960 s, -HCoV-NL63 isolated in 2004, and HCoV-HKU1identified in 2005 prompted researchers to characterize many compounds against these viruses. Most of them could be potentially active against the currently emerging novel coronavirus. Five membered nitrogen heterocycles with a triazole, imidazole, and thiazole moiety are often found in many bioactive molecules such as coronavirus inhibitors. This present work summarizes to review the biological and structural studies of these compound types as coronavirus inhibitors.
被称为SARS-CoV-2（严重急性呼吸综合征冠状病毒2）、COVID-19（2019冠状病毒病）或2019-nCoV（2019新型冠状病毒）的新型冠状病毒的传播，因其大流行潜力而成为全球关注的问题。迫切需要替代疗法来阻止这场新的大流行。如今，尚无有效的治疗方法，在许多国家，用于治愈或预防SARS-CoV-2感染的疫苗和药物仍未得到充分开发。一些候选疫苗已获批准；然而，许多人仍然对这种冠状病毒疫苗持怀疑态度。这可能是因为与疫苗数量以及仍在研究的可能的长期副作用有关的问题。以前由冠状病毒引起的感染大流行，如2003年的SARS-CoV、2012年的中东呼吸综合征冠状病毒（MERS-CoV）、HCoV-229E和HCoV-OC43在20世纪60年代被描述，2004年分离出的HCoV-NL63以及2005年鉴定出的HCoV-HKU1促使研究人员对许多针对这些病毒的化合物进行表征。其中大多数可能对当前出现的新型冠状病毒具有潜在活性。在许多生物活性分子如冠状病毒抑制剂中经常发现含有三唑、咪唑和噻唑部分的五元氮杂环。本工作总结回顾了这些化合物类型作为冠状病毒抑制剂的生物学和结构研究。
